Diagnosis and management of a severe ALK-positive pneumonia-type lung adenocarcinoma: a case report
This case highlights the importance of genetic profiling and rapid and substantial efficacy of alectinib in treating ALK-positive PLADC, reinforcing the role of ALK inhibitors in managing severe cases and offering valuable insights for clinical strategies.
Authors
- Jiani C. Yin (ORCID: https://orcid.org/0000-0002-9523-1930)
- Qibo Zhang (ORCID: https://orcid.org/0000-0002-5714-5900)
- Kai You Wang (ORCID: https://orcid.org/0000-0002-6170-4744)
- Mengyun Wang
- Qifan Jing
- Ting Su
- Jian He
Institutions
- Kunming University of Science and Technology (CN)
- Kunming Medical University (CN)
- Nanjing University of Science and Technology (CN)
- The First Hospital of Kunming (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1007/s12672-026-04890-9
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00